Latest Advanced Manufacturing News

Amaero Ltd has locked in a five-year exclusive agreement to supply spherical refractory and titanium alloy powders to Titomic, bolstering advanced manufacturing capabilities for defense and aerospace sectors.

Titomic Limited and Amaero Ltd have entered a five-year exclusive agreement to supply high-quality titanium and refractory powders, bolstering cold spray additive manufacturing for defense and aerospace sectors.

Metal Powder Works has achieved a key validation milestone for its commercially pure titanium powder, confirming performance on par with industry benchmarks for cold spray applications. This breakthrough positions MPW to expand into the lucrative aerospace and advanced manufacturing markets.

Papyrus Australia Ltd reported a sharp increase in losses for FY2025, driven by impairment of its Egyptian investments, while securing new funding and advancing commercialization of its banana fibre technology.

Powerhouse Ventures Limited reported a striking 348.8% jump in profit after tax to $1.82 million for FY25, driven by strategic acquisitions and a robust investment portfolio. The company’s first operating cash profit and growth in net tangible assets signal a turning point in its transformation.

Amaero Ltd has launched a $3 million Share Purchase Plan offering eligible shareholders in Australia and New Zealand the chance to buy new shares at $0.40 each, matching a recent placement price. The offer opens on 29 August and closes on 19 September 2025.

Advanced Braking Technology Ltd (ASX, ABV) reported a robust 25% revenue increase and 36% net profit growth for FY25, driven by international expansion and pioneering product launches in mining safety technology.

Titomic Limited reported a 22.5% increase in revenue to $9.43 million for FY2025 but saw losses soar by over 67%, highlighting ongoing financial challenges despite growth.

Tetratherix Limited advances its Tetramatrix biomaterial platform with a robust IP portfolio, scalable manufacturing, and strategic partnerships aimed at commercialising across multiple clinical franchises.

dorsaVi appoints Mathew Regan as Group CEO to spearhead commercialisation of next-gen RRAM-enabled AI and robotics technologies, aiming for global expansion.

Tetratherix Limited reports its first financial results as a listed company, revealing a $9.4 million statutory loss driven by R&D and listing costs, alongside a robust $29.3 million cash position post-IPO. The company highlights key operational milestones and outlines strategic plans to accelerate commercialisation across its innovative biomaterial platform.

Tetratherix Limited reported a $9.4 million statutory loss for FY25 amid significant R&D and operational investments, successfully listing on the ASX and progressing multiple clinical and manufacturing initiatives.